Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Directorate Change

1st Aug 2016 07:00

RNS Number : 7529F
Quantum Pharma PLC
01 August 2016
 

For immediate release

1 August 2016

 

Quantum Pharma Plc

('Quantum', the 'Company' or the 'Group')

 

Directorate Change

 

Further to the announcement issued on 12 July 2016, Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that following the resignation of Andrew Scaife as CEO the Board has appointed Chris Rigg, the Group's CFO, to Acting CEO with immediate effect.

 

Since the announcement on 12 July 2016, Chris has worked closely with Andrew on a well-managed handover of responsibilities. Andrew has now formally resigned as a director of the Company.

 

Chris was appointed CFO on 8 March 2016 having joined Quantum as the Group's Strategic Director in November 2015. Chris has a wealth of relevant experience in growing and leading businesses across a number of sectors and industries and has held a number of senior positions, including most recently CEO of Northern Recruitment Group. Other senior roles include Managing Director of eaga plc's solar division and Head of Large Corporate Lending at Barclays in the North East.

 

Chris will combine the role with his duties as CFO. A search process for a new CEO has commenced and the Company will provide an update on this in due course.

 

John Clarke, Chairman of Quantum Pharma, commented: "The Board joins me in thanking Chris for accepting the position of Acting CEO whilst we continue our search for a permanent CEO. Chris has excellent knowledge of the Group and its operations and is well placed to drive the business forward over the coming months."

- Ends -

 

 

 

For further information:

Quantum Pharma Plc

 

John Clarke, Chairman

 

Chris Rigg, Acting CEO and CFO

Tel: +44 (0) 1207 279 404

Craig Swinhoe, Group Corporate Affairs Director and Company Secretary

www.quantumpharmaplc.com

 

 

Zeus Capital Limited

(Nominated Adviser & Joint Broker)

 

Andrew Jones / Nick Cowles / Jamie Peel

Tel: +44 (0) 20 3829 5000

Dominic Wilson / John Goold

www.zeuscapital.co.uk

 

 

N+1 Singer

(Joint Broker)

 

 

Aubrey Powell / James White / Sandy Ritchie

Tel: +44 (0) 20 7496 3000

Nick Owen / Brough Ransom

 

www.n1singer.com

Media enquiries:

 

Buchanan

 

Henry Harrison-Topham / Sophie Cowles / Steph Watson

Tel: +44 (0) 20 7466 5000

quantumpharma@buchanan.uk.com

www.buchanan.uk.com

   

 

Notes to Editors

 

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

 

Specials comprises four business units (Quantum Pharmaceutical, UL Medicines, NuPharm and Quantum Aseptics Services), which manufacture, procure and supply unlicensed medicines (specials) and special obtains. In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products. With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors.  The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

 

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products) which develop and commercialise niche pharmaceuticals. This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

 

Medication Adherence comprises two business units (Biodose® and Biodose Services®) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.

 

For further information, please visit www.quantumpharmaplc.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABLGDRBSDBGLC

Related Shares:

Quantum Pharma
FTSE 100 Latest
Value8,684.56
Change50.81